• LAST PRICE
    6.1900
  • TODAY'S CHANGE (%)
    Trending Down-0.6500 (-9.5029%)
  • Bid / Lots
    5.9000/ 77
  • Ask / Lots
    6.1200/ 3
  • Open / Previous Close
    6.8100 / 6.8400
  • Day Range
    Low 6.1200
    High 6.8450
  • 52 Week Range
    Low 1.3301
    High 11.7600
  • Volume
    510,703
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeSTTK
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSTTK
Shattuck Labs Inc
325.2M
-3.2x
---
United StatesSLDB
Solid Biosciences Inc
326.6M
-2.0x
---
United StatesANRO
Alto Neuroscience Inc
323.1M
-6.3x
---
United StatesNAUT
Nautilus Biotechnology Inc
329.4M
-4.7x
---
United StatesAVXL
Anavex Life Sciences Corp
315.7M
-7.6x
---
United StatesAVIR
Atea Pharmaceuticals Inc
311.6M
-1.8x
---
As of 2024-06-15

Company Information

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Contact Information

Headquarters
500 W. 5Th Street, Suite 100AUSTIN, TX, United States 78701
Phone
512-900-4690
Fax
---

Executives

Independent Chairman of the Board
George Golumbeski
Chief Executive Officer, Co-Founder, Director
Taylor Schreiber
Chief Financial Officer
Andrew Neill
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
Stephen Stout
Chief Business Officer
Casi Deyoung

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$294.3M
Revenue (TTM)
$2.7M
Shares Outstanding
47.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.83
EPS
$-1.93
Book Value
$3.06
P/E Ratio
-3.2x
Price/Sales (TTM)
108.4
Price/Cash Flow (TTM)
---
Operating Margin
-3,327.44%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.